Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway

Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non-genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision-making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre-test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23-0.57] and 0.44 [0.21-0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2025-10-13
DOI
https://doi.org/10.1002/ijc.70194
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway

Martijn B. Busstra, Harm H.E. van Melick, Henk G. van der Poel, Aart Beeker et al.
International Journal of Cancer
BRCA gene mutations in cancer
article

Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway

Martijn B. Busstra, Harm H.E. van Melick, Henk G. van der Poel, Aart Beeker, Bart P. J. van Bezooijen, R. Jeroen A. van Moorselaar, Richard P. Meijer, H. Pieter van den Berg, Robert J. Hoekstra, Benjamin H. J. Doornweerd, Diederik M. Somford, Lambertus A.L.M. Kiemeney, Carl Wijburg, Michiel Vlaming, Eveline M. A. Bleiker, Debbie Robbrecht, Inge M. van Oort, Gina Schijven, M.A. Noordzij, Jarmo C. B. Hunting, Bart P. Wijsman, Margreet G. E. M. Ausems
article en

Abstract

Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non-genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision-making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre-test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23-0.57] and 0.44 [0.21-0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.

International Journal of CancerVol. 158(4)
University Medical Center Groningen (NL), Radboud University Nijmegen (NL), Leiden University Medical Center (NL), Catharina Ziekenhuis (NL), Radboud University Medical Center (NL), The Netherlands Cancer Institute (NL), University Medical Center Utrecht (NL), Sint Franciscus Gasthuis (NL), Spaarne Ziekenhuis (NL), St. Antonius Ziekenhuis (NL), Canisius-Wilhelmina Ziekenhuis (NL), Cancer Genomics Centre (NL), Cancer Genetics (United States) (US), Tergooi (NL), Elisabeth-TweeSteden Ziekenhuis (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), Meander Medisch Centrum (NL), Spaarne Gasthuis (NL), Vrije Universiteit Amsterdam (NL)
Openalex Percentile: Top 69%
BRCA gene mutations in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.